Seminari di Ematologia Oncologica - Società Italiana di Ematologia

26 Seminari di Ematologia Oncologica
pre-ASCT e sia nei pazienti non candidabili a
HDC+ASCT.
n BIBLIOGRAFIA
1. Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin’s lymphoma.
Cancer. 1995; 75: 370-80.
2. The non-Hodgkin's Lymphoma Classification Project.
A clinical evaluation of the International Lymphoma
Study Group classification of non-Hodgkin's
Lymphoma. Blood. 1997; 89: 3909-18.
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H,
Bouabdallah R, et al. CHOP chemotherapy plus rituximab
compared with CHOP alone in elderly patients
with diffuse large-B-cell lymphoma. N Engl J Med.
2002; 346: 235-42.
4. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G,
Plantier I, Castaigne S, et al. Blood. 2010; 116: 2040-
45.
5. Pfreundschuh M, Schubert J, Ziepert M, Schmits R,
Mohren M, Lengfelder E, et al. Six versus eight cycles
of bi-weekly CHOP-14 with or without Rituximab in elderly
patients with aggressive CD20+ B-Cell
Lymphomas: a randomised controlled trial (RICOVER-
60). Lancet Oncol. 2008; 9: 105-16.
6. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA,
Gisselbrecht C, et al. High-dose chemotherapy with
autologous stem cell support in first-line treatment of
aggressive non-Hodgkin lymphoma - Results of a comprehensive
meta-analysis. Cancer Treat Rev. 2007; 33:
338-46.
7. Shipp MA, Harrington DP: A predictive model for
aggressive NHL: the International non-Hodgkin’s lymphoma
prognostic factors project. N Engl J Med. 1993;
329: 987-94.
8. Ziepert M, Hasenclever D, Kuhnt E, Glass B,
Schmitz N, Pfrendschuh M, et al. Standard international
prognostic index remains a valid predictor of
outcome for patients with aggressive CD20+ B-cell
lymphoma in the rituximab era. J Clin Oncol. 2010;
28: 2373-80.
9. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD,
Specht L, Horning SJ, et al. Revised response criteria
for malignant lymphoma. J Clin Oncol. 2007; 25:
579-86.
10. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj
K, et al. [18-F]fluoro-2-deoxy-D-glucose positron
emission tomography in aggressive lymphoma: an early
prognostic tool for predicting patients outcome.
Blood. 2005; 106: 1376-81.
11. Cashen A, Dehdashti F, Luo J, Bartlett NL. Poor predictive
value of FDG-PET/CT performed after 2 cycles
of R-CHOP in patients with Diffuse Large B-Cell
Lymphoma (DLCL). Blood. 2008; 112: 371.
12. Vitolo U, Chiappella A, Bellò M, Passera R, Botto B,
Castellano G, et al. The outcome of patients with
Diffuse Large B-Cell Lymphoma (DLBCL) treated with
Rituximab-CHOP (R-CHOP) is not predicted by 18-
FDG-Positron Emission Tomography/Computerized
Tomography (PET) performed at intermediate incourse
evaluation, but only by PET assessed at the end
of therapy. Blood. 2010; 116: 2819.
13. World Health Organization. WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues.
Geneva, Switzerland: WHO Press. 2008.
14. Alizadeh AA, Elsen MB, Davis RE, et al. Distinct types
of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 2000; 403: 504-11.
15. Hans CP, Weisenburger DD, Greiner TC, et al.
Confirmation of the molecular classification of diffuse
large B-cell lymphoma by immunohistochemistry
using a tissue microarray. Blood. 2004; 103: 275-82.
16. Dunleavy K, Pittaluga S, Czuczman MS, et al.
Differential efficacy of bortezomib plus chemotherapy
within molecular subtypes of diffuse large B-cell lymphoma.
Blood. 2009; 113: 6069-76.
17. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli
A, De Paoli L, et al. Analysis of the host pharmacogenetic
background for prediction of outcome and toxicity
in diffuse large B-cell lymphoma treated with R-
CHOP21. Leukemia. 2009; 23: 1118-26.
18. Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F,
Gloghini A, et al. The host genetic background of DNA
repair mechanisms is an independent predictor of survival
in diffuse large B-cell lymphoma. Blood 2011; 117
(8): 2405-13.
19. Pfreundschuh M, Trumper L, Osterborg A, Pettengell
R, Trneny M, Imrie K, et al. CHOP-like chemotherapy
plus Rituximab versus CHOP-like chemotherapy alone
in young patients with good-prognosis Diffuse Large-
B-Cell Lymphoma: a randomised controlled trial by the
MabThera International Trial (MInT) Group. Lancet
Oncol. 2006; 7: 379-91.
20. Brusamolino E, Rusconi C, Montalbetti L, Gargantini
L, Uziel L, Pinotti G, et al. Dose-dense R-CHOP-14 supported
by pegfilgrastim in patients with diffuse large
B-cell lymphoma: a phase II study of feasibility and toxicity.
Haematologica. 2006; 91: 496-502.
21. Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli
M, Rambaldi A, et al. Management of nodal diffuse
large B-cell lymphomas: practice guidelines from the
Italian Society of Hematology, the Italian Society of
Experimental Hematology and the Italian Group for
Bone Marrow Transplantation. Haematologica. 2006;
91: 96-103.
22. Vitolo U, Chiappella A, Angelucci E, Rossi G, Liberati
AM, Cabras MG, et al. Dose-dense and high-dose
chemotherapy plus Rituximab with autologous stem
cell transplantation for primary treatment of diffuse
large-B-cell lymphoma at poor prognosis: a phase II
multicenter study. Haematologica. 2009; 94: 1250-8.
23. Schmitz N, Nickelsen M, Ziepert M, Haenel M,